P863 Prospective outcome following ustekinumab treatment in a real-world cohort of inflammatory bowel disease patients by Ramos Lopez, L, Ramos-Díaz, R, Benítez-Zafra, F, Morant-Domínguez, A, Vera-Santana, B, Mourani-Padrón, I, Alonso-Abreu, I, Carrillo-Palau, M, Reygosa, C, Medina-Chico, J S, Gutierrez-Nicolás, F, Nazco-Casariego, J, Hernández-Guerra, M

Get full text

P541 Efficacy, efficiency and aceptability of telemedicine for inflammatory bowel disease patients follow-up care during the COVID-19 pandemic lockdown by Ramos Lopez, L, Reygosa, C, Carrillo-Palau, M, Alonso-Abreu, I, González, Y, de la Barreda, R, Amaral, C, Hernández, A, Benítez-Zafra, F, Hernández-Guerra, M

Get full text

P694 COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy by Ramos Lopez, L, Carrillo-Palau, M, Alonso-Abreu, I, Reygosa, C, Hernández-Buylla, N, Amaral, C, Hernández, A, Benítez-Zafra, F, Pérez-González, F, Quintana-Díaz, H, Hernández-Guerra, M

Get full text

P219 Impact of COVID-19 pandemic in patients with a first consultation for suspected inflammatory bowel disease by Ramos Lopez, L, Hernández, A, Carrillo-Palau, M, Hernández-Camba, A, Alonso-Abreu, I, Reygosa, C, Vela, M, Rodríguez, G E, González-Mendez, Y, Tardillo, C, Arranz, L, Benítez-Zafra, F, Hernández-Guerra, M

Get full text